RxDoctor Payments Data

Andrea Stahl, NP

Adult Health · Mesa, AZNPI 1467701847

Payments from drug & device makers

$1,305in general payments, 2019–2025

Across 54 payments — averaging $24.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$181
  • AstraZeneca$170
  • Novartis$162
  • E.r. Squibb & Sons, L.L.C.$127
  • Lilly USA, LLC$81
  • Astellas Pharma US Inc$49
  • plus $535 from 20 others

What the payments were for

  • Food & beverage$1,305100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,305 in reported general payments places this provider in the 75th percentile of 314 adult health providers in Arizona.

See all adult health providers in Arizona

Medicare billing

Part B allowed, 2024
$3,297
Medicare patients
11
Services billed
50

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$59,700
OzempicSemaglutide31$28,965
JanuviaSitagliptin Phosphate42$23,456
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$20,224
MounjaroTirzepatide19$19,068
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog41$15,522
Fiasp FlextouchInsulin Aspart (Niacinamide)13$14,625
JardianceEmpagliflozin31$12,866
TrulicityDulaglutide13$12,168
RybelsusSemaglutide13$11,984
XareltoRivaroxaban16$8,128
Tresiba Flextouch U-200Insulin Degludec12$7,803
Aripiprazole28$3,788
Novolog FlexpenInsulin Aspart18$2,679
Rosuvastatin Calcium240$2,169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$59,70088 claims
Novo NordiskOzempic, Rybelsus$181$40,94944 claims
Lilly USA, LLCMounjaro, Trulicity$81$31,23632 claims
MerckJanuvia$46$23,45642 claims
GSKTrelegy Ellipta$43$20,22430 claims
AbbVieSynthroid$33$1,36520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 314 adult health providers in Arizona.

Other adult health in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →